Sepsis is a medical emergency.
Every minute counts!

About Immunexpress

We are pioneering the technology that analyzes the immune system to rapidly detect sepsis.

Immunexpress' technology is a paradigm shift in sepsis diagnosis—it uses blood gene expression to detect a patient's immune response to a pathogen, rather than the traditional approach which tries to identify a causative pathogen.

Our mission is to develop diagnostic technologies to help clinicians and patients to fight this life-threatening disease.

More about us


About Sepsis

Sepsis is caused by a patient’s overwhelming immune response to an infection and
leads to tissue damage, organ failure, permanent disability and often death.

Sepsis happens when pathogens trigger an overwhelming immune response.

Around the world physicians struggle to rapidly and reliably identify sepsis due to the lack of adequate diagnostic tools.

Our Technology

Traditional tests produce clinically actionable results in 24-48 hours for 20% of all patients tested. 
SeptiCyte™ LAB produces clinically actionable results in less than 90 minutes for 100% of patients tested.


How Our Technology Works


Accurate diagnosis of sepsis is time-critical to save lives.

We are partnering with Biocartis to develop a fully automated SeptiCyte® LAB cartridge compatible with the Idylla™ platform. 

How Idylla works

Together with Biocartis we aim to improve clinical and economic outcomes to benefit all key healthcare stakeholders, medical professionals, payers and patients.

Biocartis’ sample-to-result Idylla™ platform


Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021


Use of SeptiCyte® RAPID Assay to Assess the Risk of ICU admission in COVID-19 Patients

MedTech Gurus

Finding The Product- Market Fit, with Rollie Carlson Ph.D. CEO of Immunexpress